Pharmaceutical · Fiscal year end Mar 31

KISSEI PHARMACEUTICAL CO.,LTD.

4547

キッセイ薬品工業株式会社

FIGI BBG000BJSCQ04547.T4547 JPCorp. no. 1100001012982

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-10

For the first half of the fiscal year to 2026-03: Revenue ¥45.8 billion (+7.9% YoY), Ordinary income ¥-5.6 billion (-351.3% YoY), Net income ¥7.8 billion (+48.3% YoY).

	This period	Year on year
Revenue	¥45.8bn	+7.9%
Ordinary profit	−¥5.6bn	-351.3%
Net profit to owners	¥7.8bn	+48.3%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4547/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31

Revenue: ¥97.4bn
Net income: ¥13.8bn
ROE: 6.3%
Equity ratio: 83.7%
Dividend / share: ¥160
Employees: 1,786

Revenue · ¥bn

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2026-03-31	¥97.4bn	¥13.8bn	¥275.1bn	¥231.5bn	6.3%	¥331.54	−¥1.5bn
2025-03-31	¥88.3bn	¥12.0bn	¥244.1bn	¥210.1bn	5.6%	¥274.21	¥6.5bn
2024-03-31	¥75.6bn	¥11.2bn	¥260.9bn	¥221.1bn	5.4%	¥246.61	−¥1.7bn
2023-03-31	¥67.5bn	¥10.5bn	¥221.2bn	¥194.8bn	5.3%	¥228.31	−¥6.7bn
2022-03-31	¥65.4bn	¥12.9bn	¥238.1bn	¥202.2bn	6.1%	¥280.2	¥1.5bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31

Metric	Value	Percentile among listed companies
ROE, %	6.3	34.1
Ordinary margin	-0.0119	8.2
Equity ratio, %	83.7	93.7
Revenue growth	0.1028	70.1
Net income growth	0.152	51.5
Operating cash flow / assets	-0.0054	14.9

Policy-uncertainty measure1.69 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Trade & tariffs 1 Fiscal & tax 1 Regulation 2 Politics & geopolitics 1

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 14.9% held by other listed companies.

Results wording balance: +0.50. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥1.3bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥6m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4547/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Share buyback, report to —: ¥730m acquired of a ¥6.0bn limit. /v1/companies/4547/buybacks

Internal control, 2026-06-22: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Segments: Pharmaceutical Products, Information Service, Construction and Facility Maintenance Business, Trading Business. /v1/companies/4547/segments

Latest voting result: 2026-06-23 · 剰余金の処分の件 · passed. /v1/companies/4547/voting

Ownership changes

All companies →

2024-05-20

New 5% stake

Brandes Investment Partners, L.P. disclosed a 5.15% stake in KISSEI PHARMACEUTICAL CO.,LTD. (4547), crossing the 5% reporting threshold.

S100TGNBFiler profile Original filing (PDF, Japanese)
2024-03-22

Below 5%−1.13pt

Hachijuni Nagano Bank, Ltd. cut holdings in KISSEI PHARMACEUTICAL CO.,LTD. (4547) to 4.47% from 5.60%, below the 5% threshold.

S100T2I9Filer profile Original filing (PDF, Japanese)
2024-01-05

Decrease−1.01pt

Hachijuni Nagano Bank, Ltd. reduced holdings in KISSEI PHARMACEUTICAL CO.,LTD. (4547) to 5.60% from 6.61%.

S100SK2ZFiler profile Original filing (PDF, Japanese)
2023-06-08

New 5% stake

Hachijuni Nagano Bank, Ltd. disclosed a 6.61% stake in KISSEI PHARMACEUTICAL CO.,LTD. (4547), crossing the 5% reporting threshold.

S100QTD4Filer profile Original filing (PDF, Japanese)
2022-04-21

Below 5%−1.05pt

The Dai-ichi Life Insurance Company, Limited cut holdings in KISSEI PHARMACEUTICAL CO.,LTD. (4547) to 4.87% from 5.92%, below the 5% threshold.

S100NXMHFiler profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
株式会社八十二銀行	2024-03-15 – 2024-03-15	-97,000	−0.20pt	¥3,660	¥3,660–3,660
株式会社長野銀行	2023-11-07 – 2024-03-05	-1,004,692	−2.04pt	¥3,160.04	¥3,160–3,400

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4547/trades.

5% filings

Large shareholding reports on 4547

Filed	Filer	Stake	Change	Stated purpose
2024-05-20	Brandes Investment Partners, L.P.	5.15%	—	—
2024-03-22	Hachijuni Nagano Bank, Ltd.	4.47%	−1.13pt	strategic holding
2024-01-05	Hachijuni Nagano Bank, Ltd.	5.60%	−1.01pt	strategic holding
2023-06-08	Hachijuni Nagano Bank, Ltd.	6.61%	—	strategic holding
2022-04-21	The Dai-ichi Life Insurance Company, Limited	4.87%	−1.05pt	pure investment

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: 18 issues
Book value: ¥32.0bn
Sold in the year: ¥4.6bn 3 issues
Bought in the year: — — issues
Mutual, both reports: 15
Held by listed cos.: 30

Holds	Book value	Shares vs. prior year	Mutual
Shionogi & Co.,Ltd. 4507	¥11.2bn	0.0%	both reports
株式会社八十二長野銀行 (注)２	¥6.3bn	0.0%	stated
Mizuho Leasing Company, Limited 8425	¥1.9bn	-30.0%	both reports
ZERIA PHARMCEUTICAL CO., LTD. 4559	¥1.9bn	0.0%	both reports
TOHO HOLDINGS CO.,LTD. 8129	¥1.7bn	0.0%	both reports
WAKAMOTO PHARMACEUTICAL CO.,LTD. 4512	¥1.3bn	0.0%	both reports
KYORIN Pharmaceutical Co., Ltd. 4569	¥1.1bn	0.0%	both reports
MEDIPAL HOLDINGS CORPORATION 7459	¥1.1bn	0.0%	both reports
HOKUTO CORPORATION 1379	¥1.0bn	0.0%	both reports
DAIICHI SANKYO COMPANY, LIMITED 4568	¥0.9bn	-74.1%	both reports

Held by: Hachijuni Nagano Bank, Ltd. 8359, Shionogi & Co.,Ltd. 4507, Daiwa Securities Group Inc. 8601, HOKUTO CORPORATION 1379, KYORIN Pharmaceutical Co., Ltd. 4569, DAIICHI SANKYO COMPANY, LIMITED 4568, Taikisha Ltd. 1979, ZERIA PHARMCEUTICAL CO., LTD. 4559, ZERIA PHARMCEUTICAL CO., LTD. 4559, WAKAMOTO PHARMACEUTICAL CO.,LTD. 4512, Nippon Shinyaku Co.,Ltd. 4516, TSUMUGU Holdings, Inc. 3055 and 20 more

Purposes, all holdings and mutual flags via /v1/companies/4547/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31

Shareholder	Shares	Ratio
日本マスタートラスト信託銀行株式会社(信託口)	5,033,000	12.14%
株式会社八十二長野銀行	2,063,000	4.98%
株式会社日本カストディ銀行（信託口）	1,840,000	4.44%
有限会社カンザワ	1,678,000	4.05%
individual holder	1,550,000	3.74%
第一生命保険株式会社	1,344,000	3.24%
鍋林株式会社	1,222,000	2.95%
キッセイグループ従業員持株会	1,212,000	2.93%
STATE STREET BANK AND TRUST COMPANY 505103	1,112,000	2.68%
塩野義製薬株式会社	914,000	2.20%

U.S. funds holding 4547

SEC Form N-PORT, reports to 2026-07-31

46 U.S. funds held 2,865,252 shares worth $72.8m.

Fund	Shares	Value	% of fund	As of
Brandes International Small Cap Equity Fund Datum One Series Trust	606,700	$15.3m	1.183%	2026-06-30
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS	462,801	$11.8m	0.002%	2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS	311,658	$7.9m	0.002%	2026-06-30
THE JAPANESE SMALL COMPANY SERIES DFA INVESTMENT TRUST CO	193,300	$4.9m	0.123%	2026-07-31
iShares Core MSCI EAFE ETF iShares Trust	164,600	$4.2m	0.002%	2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4547
GET /v1/companies/4547/financials
GET /v1/companies/4547/details
GET /v1/companies/4547/segments
GET /v1/companies/4547/voting
GET /v1/companies/4547/tender-offers
GET /v1/companies/4547/indicators
GET /v1/companies/4547/earnings-releases
GET /v1/events?ticker=4547
GET /v1/companies/4547/trades         
GET /v1/companies/4547/cross-holdings 
GET /v1/companies/4547/brief

Plans from $9 a month · Documentation